Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amylin Pharmaceuticals has made two senior management changes by appointing Christian Weyer as senior vice president of R&D and Orville Kolterman as senior vice president and chief medical officer, to focus on its preparations for a new product launch and the advancement of its late-stage development programs.
Subscribe to our email newsletter
Mr Weyer will lead Amylin’s R&D organization, focusing on expanding opportunities with the company’s existing diabetes products, advancing the obesity and early diabetes pipeline, and driving research programs that support innovation and business growth.
Mr Weyer held various leadership roles during his 10-year tenure at Amylin in the research, clinical, and corporate development organizations, and most recently as vice president of medical development.
Mr Kolterman will work to further strengthen Amylin’s ties with the medical community, policy-makers, patient advocacy groups, and other audiences that will be critical in supporting the launch of Bydureon (exenatide for extended-release injectable suspension) and driving therapeutic innovation for patients.
He will also continue to lead interactions with regulatory agencies and have responsibility for global safety activities. Mr Kolterman was previously senior vice president of research and development.
Daniel Bradbury, president and CEO of Amylin Pharmaceuticals, said: “The changes announced today will sharpen Amylin’s focus in areas that are critical to our near- and long-term success. Chris is a seasoned R&D leader with a strong scientific background in endocrinology and metabolism, as well as solid business and management experience.
“His proven ability to expand and enable the Amylin pipeline will be invaluable in his new leadership role as we continue progress on promising programs that could transform the lives of patients.”